ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 965,19
1,87%
DAX
18 518,03
-0,44%
Brent Oil
83,265
-1,27%
Bitcoin
65 063,24
0,33%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Portola Pharmaceuticals Inc (PTLA)

  7. Portola Pharmaceuticals Inc (PTLA) Actualités

PTLA

Portola Pharmaceuticals (PTLA)

Portola Pharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PTLA
DateHeureSourceTitreSymboleSociété
20/02/201822h47GlobeNewswire Inc.Portola Pharmaceuticals Announces Results of CHMP Oral Explanations for Andexanet Alfa and BetrixabanNASDAQ:PTLAPortola Pharmaceuticals Inc
15/02/201822h05GlobeNewswire Inc.Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesda...NASDAQ:PTLAPortola Pharmaceuticals Inc
14/02/201823h15Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:PTLAPortola Pharmaceuticals Inc
12/02/201816h01Edgar (US Regulatory)Schedule 13gNASDAQ:PTLAPortola Pharmaceuticals Inc
06/02/201822h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PTLAPortola Pharmaceuticals Inc
23/01/201803h33GlobeNewswire Inc.Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18NASDAQ:PTLAPortola Pharmaceuticals Inc
22/12/201723h23GlobeNewswire Inc.Portola Pharmaceuticals Provides Update on Biologics License Application (BLA) for AndexXa® (andexanet alfa)NASDAQ:PTLAPortola Pharmaceuticals Inc
22/12/201714h00GlobeNewswire Inc.Portola Pharmaceuticals to Webcast Corporate Update on January 9, 2018NASDAQ:PTLAPortola Pharmaceuticals Inc
19/12/201716h35GlobeNewswire Inc.U.S. Food and Drug Administration Approves Prior Approval Supplement for Commercial Launch of Portola Pharmaceuticals’ Nove...NASDAQ:PTLAPortola Pharmaceuticals Inc
12/12/201714h30GlobeNewswire Inc.Portola Pharmaceuticals Provides Update on European Marketing Authorization Application for BetrixabanNASDAQ:PTLAPortola Pharmaceuticals Inc
05/12/201722h14GlobeNewswire Inc.Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
01/12/201723h36Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PTLAPortola Pharmaceuticals Inc
30/11/201714h00GlobeNewswire Inc.Portola Pharmaceuticals to Present New Data on Betrixaban, Andexanet Alfa and Cerdulatinib at the 59th American Society of He...NASDAQ:PTLAPortola Pharmaceuticals Inc
22/11/201700h22GlobeNewswire Inc.Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial LaunchNASDAQ:PTLAPortola Pharmaceuticals Inc
09/11/201723h11Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:PTLAPortola Pharmaceuticals Inc
09/11/201712h09Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PTLAPortola Pharmaceuticals Inc
08/11/201723h29Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:PTLAPortola Pharmaceuticals Inc
07/11/201714h00GlobeNewswire Inc.Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Associa...NASDAQ:PTLAPortola Pharmaceuticals Inc
06/11/201722h01GlobeNewswire Inc.Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateNASDAQ:PTLAPortola Pharmaceuticals Inc
06/11/201714h00GlobeNewswire Inc.Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President of Product Development and...NASDAQ:PTLAPortola Pharmaceuticals Inc
03/11/201713h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at the Credit Suisse 26th Annual Healthcare ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
30/10/201713h00GlobeNewswire Inc.Portola Pharmaceuticals to Announce Third Quarter 2017 Financial Results and Host Conference Call on Monday, November 6NASDAQ:PTLAPortola Pharmaceuticals Inc
11/10/201722h05GlobeNewswire Inc.Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clo...NASDAQ:PTLAPortola Pharmaceuticals Inc
03/10/201722h05GlobeNewswire Inc.Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:PTLAPortola Pharmaceuticals Inc
13/09/201722h26Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:PTLAPortola Pharmaceuticals Inc
13/09/201704h39GlobeNewswire Inc.Portola Announces Pricing of Public Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
11/09/201722h01GlobeNewswire Inc.Portola Pharmaceuticals Announces Proposed Offering of Common StockNASDAQ:PTLAPortola Pharmaceuticals Inc
06/09/201714h00GlobeNewswire Inc.Portola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare ConferenceNASDAQ:PTLAPortola Pharmaceuticals Inc
05/09/201714h00GlobeNewswire Inc.Reminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on B...NASDAQ:PTLAPortola Pharmaceuticals Inc
02/09/201700h34GlobeNewswire Inc.Portola Pharmaceuticals to Host Webcast and Conference Call Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixa...NASDAQ:PTLAPortola Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:PTLA

Dernières Valeurs Consultées

BOV
EZTCG136
EZTCG136 Ex:13,6
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés